PCP2, can effectively measure PD-L1 expression in patients with head and neck cancers, outperforming the conventional tracer ...

VIENNA, Va., June 18, 2025--FDA’s Approval of Keytruda for PD-L1 Positive Head and Neck Cancer Patients Signals a Clear Pathway for CEL-SCI’s Multikine.

Pembrolizumab, an immune checkpoint inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with resectable locally advanced head and neck squamous ...

Conservation of PD-1 and PDL-1 interaction between fish and mammals. The figures show superimpositions of the (membrane-distant) IgSF domains of human PD-1 bound to human PD-L1 (PDB accession 4ZQK ...

Background: Squamous cell lung carcinoma (sqNSCLC) accounts for 25-30% of all non-small cell lung cancer (NSCLC) cases and is associated with poor prognosis. Although the addition of anti-PD (L)1 ...

Key Takeaways Solnerstotug showed a 14% response rate and 62% disease control in PD-L1 resistant tumors, surpassing typical expectations. Significant responses were observed in Merkel cell carcinoma ...

PD-L1 is a critical biomarker for potential response to anti-PD-1 therapies, which are revolutionizing the treatment of cancer. Pathology labs play an important role in informing treatment decisions.

8.1 Market Overview 8.2 PD-1 Antibody Market 8.3 PD-L1 Antibody Market 8.4 Bispecific PD-1xCTLA-4 and PD-1xLAG-3 Antibody Market 8.5 Other PD- (L1) Antibodies without Information on Sales ...

In an 11 to 1 vote, the FDA’s Oncologic Drug Advisory Committee (ODAC) voted that the risk-benefit assessment is not favorable for the use of checkpoint inhibitors (CPIs) in patients with metastatic ...

Published Sept. 12, 2024. Accessed Sept. 13, 2024. FDA approves Genentech’s Tecentriq Hybreza, the first and only subcutaneous anti-PD- (L)1 cancer immunotherapy (press release).

The investigational PD-1/VEGF bi-specific immunotherapy agent showed a clinically significant progression-free survival over pembrolizumab in advanced PD-L1-positive NSCLC.

In PD-L1-negative patients, the size of improvement fell to just 8% versus chemo alone. The death-risk reduction in the all-comers population, at 20%, met statistical significance.